Timber Pharmaceuticals Long Term Debt

Timber Pharmaceuticals (TMBR) currently reports a long-term debt of $320K as of June 2023. That compares with $160K in the prior-year period — up 96.8% year over year. Use the charts on this page to explore Timber Pharmaceuticals's long-term debt history and peer comparisons.

Timber Pharmaceuticals's long-term debt increased from $160K to $320K — a 96.8% year-over-year increase (period ending June 2023). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Timber Pharmaceuticals reported $320K in long-term debt as of June 2023. That compares with $160K in the prior-year period — up 96.8% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current long-term debt of $320K, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Timber Pharmaceuticals, and consider following TMBR for alerts when major investors trade the stock.

Timber Pharmaceuticals is classified in the Healthcare sector. On long-term debt, it currently shows $320K. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing TMBR with unrelated industries.